Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00453622 · ClinicalTrials.gov registry record

RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D

A clinical trial of Heart Failure, sponsored by Abbott Medical Devices.

Completed
Registry status
222
Enrollment target
1
Study location

NCT00453622: Completed study of Heart Failure, sponsored by Abbott Medical Devices.

NCT00453622 is a study of Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 222 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00453622, a study of Heart Failure, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
222 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to identify if the combined use of cardiac troponin enzyme (cTnT) and brain natriuretic peptide (BNP) can predict Heart Failure (HF)improvement and all-cause mortality in patients implanted with cardiac pacemaker-defibrillation devices (CRT-D). Novel biochemical markers identifying patients with high risk cardiac mortality detected by plasma protein analysis will also be evaluated. Hypothesis #1: The combined use of cTnT and BNP at just before implant will predict and risk stratify all cause mortality or HF hospitalization up to 12 months. Hypothesis #2: The change in levels of said biomarkers at different points of follow-up can predict response to CRT through 12 months. Hypothesis #3: The levels of a panel of novel inflammatory mediators, namely chemokines, will be correlated with improvement in 6-minute walk testing, quality of life, and left ventricular ejection fraction in CRT patients.

Conditions Studied

Interventions

  • DEVICE Cardiac Resynchronization Therapy-Defibrillator

Study Locations (1)

Pennsylvania

  • Veterans' Adminstration Pittsburgh Healthcare System - Pittsburgh

Trial Details

FieldValue
Enrollment Target 222 participants
Start Date 2005-11
Est. Completion 2012-08
Abbott Medical Devices

261 total trials

What the finished NCT00453622 record still lists

NCT00453622 is an observational study that tracks outcomes without assigning an intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Resynchronization Therapy-Defibrillator is the first listed.

NCT00453622 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00453622 about?

NCT00453622 is a clinical study titled "RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D". The purpose of the study is to identify if the combined use of cardiac troponin enzyme (cTnT) and brain natriuretic peptide (BNP) can predict Heart Failure (HF)improvement and all-cause mortality in patients implanted with cardiac pacemaker-defibrillation devices (CRT-D). Novel biochemical markers i...

What is the current status of trial NCT00453622?

This trial is currently completed. The enrollment target is 222 participants. The study started on 2005-11. Estimated completion is 2012-08.

What conditions does trial NCT00453622 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT00453622?

The interventions under investigation include: Cardiac Resynchronization Therapy-Defibrillator (DEVICE).

Who is sponsoring clinical trial NCT00453622?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00453622 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00453622's enrollment target sits among peer trials

222 158th of 397 higher than 240 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04939610 · 222 participants · Phase 1

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

  • NCT05424783 · 222 participants

    MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

  • NCT05568264 · 222 participants · NA

    Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

  • NCT05605574 · 222 participants · NA

    Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00453622, the US trial registry maintained by the National Library of Medicine. NCT00453622 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.